Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHB3 | P54753 | 18/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.72 |
| ▸ | LCK | P06239 | 1/20 | 0.72 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2874133 | 0.88 | EPHB3 (1.00) | EPHB3RIPK2LCK | |
| SCHEMBL2875390 | 0.85 | EPHB3 (1.00) | EPHB3RIPK2LCKNPC1 | |
| SCHEMBL2874478 | 0.85 | EPHB3 (1.00) | EPHB3RIPK2LCKNPC1RAB9A | |
| SCHEMBL2878098 | 0.85 | EPHB3 (1.00) | EPHB3RIPK2LCK | |
| SCHEMBL22170113 | 0.84 | EPHB3 (1.00) | EPHB3RIPK2LCKLMNAHTT | |
| SCHEMBL2879861 | 0.83 | EPHB3 (0.73) | EPHB3RIPK2LCK | |
| SCHEMBL2877098 | 0.81 | EPHB3 (0.98) | EPHB3RIPK2LCK | |
| SCHEMBL2875231 | 0.80 | EPHB3 (1.00) | EPHB3RIPK2LCK | |
| SCHEMBL2878118 | 0.79 | EPHB3 (1.00) | EPHB3RIPK2LCKNPC1RAB9A | |
| SCHEMBL2875489 | 0.79 | EPHB3 (1.00) | EPHB3RIPK2LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010117787-A2 | INHIBITING EPH B-3 KINASE | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2010-10-14 | — | — | WO | claimed |
| US-8927545-B2 | Inhibiting Eph B-3 kinase | DUKE UNIVERSITY (US) | 2015-01-06 | — | — | US | disclosed |
| US-20120238597-A1 | Inhibiting EPH B-3 Kinase | DUKE UNIVERSITY (US) | 2012-09-20 | — | — | US | disclosed |
| WO-2010117787-A2 | INHIBITING EPH B-3 KINASE | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| JP-2010504962-A | — | アストラゼネカ・アクチエボラーグＡＳＴＲＡＺＥＮＥＣＡ ＡＫＴＩＥＢＯＬＡＧ | 2010-02-18 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238597-A1 | Inhibiting EPH B-3 Kinase | EPHB3, EPHB1, EPHB2 | EPHB3 1/4885RIPK2 173/4885LCK 612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.